Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT03720262
Recruiting Phase 2/3

Prevention of Hernia After Loop Ileostomy Reversal

NCT03720262 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska Institutet
Phase
Phase 2/3
Started
2018-03-01
Last updated
2025-08-19

Condition(s) studied

Loop Ileostomy

Investigational drug(s) / intervention(s)

Mesh reinforcementNo reinforcement

Mesh reinforcement: Reinforcement of the abdominal wall with Ultrapro Advanced.

No reinforcement: Suturing the abdominal wall without mesh reinforcement

Study summary

PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery are randomized between retro muscular mesh Ultrapro Advanced or standard treatment without mesh.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients operated for low anterior resection for rectal cancer with a diverting loop ileostomy and planned for stoma reversal Exclusion Criteria: * Language barrier or cognitive disability * Recurrent cancer

Primary outcome measure(s)

  • Hernia — One year
    Hernia at the site of the stomal closure

Trial sites (4)

FacilityCityRegionStatus
Södertälje Hospital Södertälje Sweden Recruiting
Stockholm South General Hospital Stockholm Sweden Recruiting
Ersta Hospital Stockholm Sweden Recruiting
Västmanland Hospital Västerås Sweden Recruiting

More Karolinska Institutet trials in Sweden

A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplantation Recruiting
A Digital Lifestyle Intervention in Primary Healthcare to Prevent Cardiovascular Disease Recruiting
Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions Active, not recruiting
Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events Active, not recruiting
Internet-delivered Emotion Regulation Individual Therapy or Adolescents (IERITA) With Self-injury Within Child and Adolescent Mental Health Services Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03720262 on ClinicalTrials.gov ↗ ← All trials in Sweden